Carley is a writer, editor and social media professional. Before starting at Forbes Health, she wrote for Sleepopolis and interned at PBS and Nickelodeon. She’s a certified sleep science coach and ...
With the recent launches of Novo Nordisk’s Wegovy pill and Eli Lilly’s Foundayo, the obesity market has started to shift toward oral GLP-1 drugs. While Novo leverages its first-mover advantage with ...
After capturing the North American market with Wegovy (semaglutide) and Zepbound (tirzepatide), Novo Nordisk A/S and Eli Lilly and Co. are advancing blockbuster glucagon-like peptide-1 (GLP-1) ...
Microdosing GLP-1 weight loss drugs like semaglutide is trendy, with supporters touting benefits such as lower costs and potentially fewer side effects. But some doctors are skeptical, calling it ...
People who reach a healthy weight and improve their metabolic health on GLP-1 medications are typically told they’ll need to maintain a weekly dose indefinitely to keep the weight off. But emerging ...
Everyday Health independently vets all recommended products. If you purchase a featured product, we may be compensated. Learn why you can trust us. Everyday Health independently vets all recommended ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results